Compare Stocks: PMCB, MRKR, TCRX, and BCDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$0.92 -2.0%	$1.06	$0.75 ▼ $1.80	$14.21M	0.62	246,414 shs	104,789 shs
MRKR Marker Therapeutics	$1.04 +13.0%	$1.17	$0.84 ▼ $2.46	$15.34M	1.53	86,015 shs	1.15 million shs
PMCB Nuvilex	$0.34 -4.8%	$0.46	$0.33 ▼ $1.51	$3.84M	0.68	158,116 shs	32,984 shs
TCRX TScan Therapeutics	$0.23 -3.5%	$0.47	$0.20 ▼ $2.57	$16.22M	1.15	701,182 shs	568,221 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	+1.22%	-11.46%	-23.70%	+13.65%	-39.84%
MRKR Marker Therapeutics	+3.35%	-3.16%	-21.37%	-29.77%	-12.38%
PMCB Nuvilex	+2.55%	-10.07%	-6.51%	-43.54%	-64.61%
TCRX TScan Therapeutics	+13.63%	+4.86%	-25.52%	-73.84%	-89.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$0.92 -2.0%	$1.06	$0.75 ▼ $1.80	$14.21M	0.62	246,414 shs	104,789 shs
MRKR Marker Therapeutics	$1.04 +13.0%	$1.17	$0.84 ▼ $2.46	$15.34M	1.53	86,015 shs	1.15 million shs
PMCB Nuvilex	$0.34 -4.8%	$0.46	$0.33 ▼ $1.51	$3.84M	0.68	158,116 shs	32,984 shs
TCRX TScan Therapeutics	$0.23 -3.5%	$0.47	$0.20 ▼ $2.57	$16.22M	1.15	701,182 shs	568,221 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	+1.22%	-11.46%	-23.70%	+13.65%	-39.84%
MRKR Marker Therapeutics	+3.35%	-3.16%	-21.37%	-29.77%	-12.38%
PMCB Nuvilex	+2.55%	-10.07%	-6.51%	-43.54%	-64.61%
TCRX TScan Therapeutics	+13.63%	+4.86%	-25.52%	-73.84%	-89.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCDA BioCardia	2.00	Hold	$25.00	2,617.10% Upside
MRKR Marker Therapeutics	2.25	Hold	$10.00	861.54% Upside
PMCB Nuvilex	1.00	Sell	N/A	N/A
TCRX TScan Therapeutics	2.13	Hold	$2.67	1,054.40% Upside

Current Analyst Ratings Breakdown

Latest PMCB, MRKR, TCRX, and BCDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	BCDA BioCardia	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/2/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/18/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	TCRX TScan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral	$1.00
9/4/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	PMCB Nuvilex	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	TCRX TScan Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
8/24/2026	BCDA BioCardia	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/21/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCDA BioCardia	$60K	232.17	N/A	N/A	$0.08 per share	11.50
MRKR Marker Therapeutics	$3.55M	4.88	N/A	N/A	$1.01 per share	1.03
PMCB Nuvilex	N/A	N/A	N/A	N/A	$3.10 per share	N/A
TCRX TScan Therapeutics	$10.32M	1.52	N/A	N/A	$2.16 per share	0.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCDA BioCardia	-$8.23M	-$0.64	N/A	N/A	N/A	N/A	-569.36%	-183.15%	11/11/2026 (Estimated)
MRKR Marker Therapeutics	-$12.16M	-$0.41	N/A	N/A	N/A	N/A	-56.96%	-47.82%	11/12/2026 (Estimated)
PMCB Nuvilex	-$19.42M	-$2.31	N/A	N/A	N/A	N/A	-12.99%	-8.92%	12/16/2026 (Estimated)
TCRX TScan Therapeutics	-$129.77M	-$0.91	N/A	N/A	N/A	-1,655.35%	-108.72%	-54.47%	11/11/2026 (Estimated)

Latest PMCB, MRKR, TCRX, and BCDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	MRKR Marker Therapeutics	-$0.12	N/A	N/A	N/A	$2.12 million	N/A
11/11/2026	Q3 2026	BCDA BioCardia	-$0.15	N/A	N/A	N/A	N/A	N/A
11/11/2026	Q3 2026	TCRX TScan Therapeutics	-$0.18	N/A	N/A	N/A	$0.46 million	N/A
9/14/2026	Q1 2027	PMCB Nuvilex	-$0.06	-$0.54	-$0.48	-$0.54	N/A	N/A
8/14/2026	Q2 2026	MRKR Marker Therapeutics	-$0.25	-$0.09	+$0.16	-$0.09	$0.68 million	N/A
8/12/2026	Q2 2026	BCDA BioCardia	-$0.18	-$0.13	+$0.05	-$0.13	N/A	N/A
8/12/2026	Q2 2026	TCRX TScan Therapeutics	-$0.2534	-$0.23	+$0.0234	-$0.23	$1.88 million	$1.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
PMCB Nuvilex	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCDA BioCardia	N/A	2.09	2.09
MRKR Marker Therapeutics	N/A	6.03	6.03
PMCB Nuvilex	N/A	40.28	40.28
TCRX TScan Therapeutics	0.31	3.37	3.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCDA BioCardia	20.57%
MRKR Marker Therapeutics	22.39%
PMCB Nuvilex	34.24%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
BCDA BioCardia	17.40%
MRKR Marker Therapeutics	5.70%
PMCB Nuvilex	10.98%
TCRX TScan Therapeutics	6.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCDA BioCardia	21	15.14 million	12.51 million	Optionable
MRKR Marker Therapeutics	60	16.67 million	15.72 million	Not Optionable
PMCB Nuvilex	2	10.74 million	9.56 million	Optionable
TCRX TScan Therapeutics	142	67.78 million	63.54 million	Not Optionable

PMCB, MRKR, TCRX, and BCDA Headlines

Recent News About These Companies

TScan Therapeutics Announces Board and Governance Changes

October 16 at 5:30 PM | tipranks.com

Financial Analysis: argenex (NASDAQ:ARGX) vs. TScan Therapeutics (NASDAQ:TCRX)

October 15 at 2:46 AM | americanbankingnews.com

TScan Therapeutics consensus price target decreased by 55.56% to $2.72

September 16, 2026 | msn.com

Wedbush downgrades TScan Therapeutics (TCRX) to neutral from outperform

September 3, 2026 | msn.com

TScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%

September 2, 2026 | rttnews.com

TScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor program

September 2, 2026 | msn.com

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

September 2, 2026 | benzinga.com

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

September 2, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)

August 13, 2026 | theglobeandmail.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

August 12, 2026 | zacks.com

TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results

August 12, 2026 | quiverquant.comQ

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | globenewswire.com

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

July 29, 2026 | globenewswire.com

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 24, 2026 | globenewswire.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...

June 23, 2026 | markets.businessinsider.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

June 22, 2026 | globenewswire.com

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

June 3, 2026 | businesswire.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

June 2, 2026 | insidermonkey.com

TScan Therapeutics Expands Authorized Shares After Stockholder Vote

May 22, 2026 | tipranks.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

May 6, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB, MRKR, TCRX, and BCDA Company Descriptions

BioCardia NASDAQ:BCDA

$0.92 -0.02 (-1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$0.92 0.00 (-0.23%)

As of 07:21 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Marker Therapeutics NASDAQ:MRKR

$1.04 +0.12 (+13.04%)

Closing price 04:00 PM Eastern

Extended Trading

$1.02 -0.02 (-1.83%)

As of 07:59 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Nuvilex NASDAQ:PMCB

$0.34 -0.01 (-4.03%)

As of 04:00 PM Eastern

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

TScan Therapeutics NASDAQ:TCRX

$0.23 -0.01 (-3.47%)

Closing price 04:00 PM Eastern

Extended Trading

$0.23 +0.00 (+0.43%)

As of 07:58 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMCB, MRKR, TCRX, and BCDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMCB, MRKR, TCRX, and BCDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMCB, MRKR, TCRX, and BCDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB, MRKR, TCRX, and BCDA Company Descriptions

BioCardia NASDAQ:BCDA

Marker Therapeutics NASDAQ:MRKR

Nuvilex NASDAQ:PMCB

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMCB, MRKR, TCRX, and BCDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMCB, MRKR, TCRX, and BCDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMCB, MRKR, TCRX, and BCDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB, MRKR, TCRX, and BCDA Company Descriptions

BioCardia NASDAQ:BCDA

Marker Therapeutics NASDAQ:MRKR

Nuvilex NASDAQ:PMCB

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools